A.P. Pharma's CEO resigns

A.P. Pharma President and CEO Ronald Prentki has resigned due to differences of opinion in regulatory strategy. Release

Senesco Technologies has named biopharmaceutical executive Leslie Browne as president and CEO. Release

Novavax has appointed Mark Thornton as its senior VP, development and chief medical officer. Release

Lukas Utiger, currently COO Lonza Life Science Ingredients, will become the new COO of Lonza Bioscience, located in Walkersville, Maryland.  He will replace Anja Fiedler who resigned due to personal health reasons. Stefan Borgas, CEO, will take over the leadership of the Life Science Ingredients business in addition to his current responsibilities for the next few months until a successor will be named. Release

Aastrom Biosciences has named Sharon Watling as VP, clinical and regulatory, and Ronnda Bartel, formerly vice president of technical operations, as chief scientific officer. Release

Peter Ruppersberg is leaving the advisory board of PANATecs. His successor is Rainer Baule, member of the board of Fresenius SE and chairman of the board of Fresenius Kabi AG. Release

ElexoPharm has announced the appointment of Jürgen Engel as chairman of its advisory board. Release

Geron has appointed Hoyoung Huh and Robert Spiegel to its board of directors. Release

aTyr has announced that John Mendlein has joined its board of directors as executive chairman. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.